Skip to main content

Table 2 COX-2 haplotype and risk for breast cancer: Long Island Breast Cancer Study Project, 1996 to 1997

From: Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk

COX-2 haplotype/diplotype status

Cases (n )

Controls (n )

Adjusted OR (95% CI)a

P value

Haplotypeb

    

   GTT

1,359

1,405

1.0 (ref.)

 

   CGC

363

388

1.0 (0.8–1.2)

0.85

   GTC

299

306

1.0 (0.8–1.2)

0.95

   GGC

38

60

0.7 (0.5–1.0)

0.06

   CTT

27

33

0.8 (0.5–1.4)

0.48

Diplotype (haplotype pairs)

    

   GTT GTT

434

432

1.0 (ref.)

 

   GTT CGC

239

262

0.9 (0.7–1.1)

0.45

   GTT GTC

186

194

1.0 (0.7–1.2)

0.69

   GTC CGC

49

51

0.9 (0.6–1.4)

0.79

   GTC GTC

26

25

1.0 (0.6–1.8)

0.94

   GTT GGC

12

27

0.5 (0.2–0.9)c

0.03

   GTT CTT

19

24

0.7 (0.4–1.4)

0.36

   CGC CGC

25

23

1.1 (0.6–2.1)

0.68

   Others

47

36

1.3 (0.8–2.0)

0.31

  1. aAdjusted for age at reference. b COX-2 haplotype composed of three polymorphic sites: COX-2.926 G→C, COX-2.5209 T→G, and COX-2.8473 T→C. cThe comparison with all other diplotype combinations was also statistically significant (OR = 0.5, 95% CI = 0.2 to 0.9; P = 0.03). CI, confidence interval; OR, odds ratio.